"I have consistently expressed my concern to the committee that I do not think requiring a reduction in price for a streamlined cost pathway is an appropriate way forward," said Medicines Australia chief executive Liz de Somer.
'If it is necessary for me to formally dissent in the final report, I will do so'
February 1, 2024 Latest NewsBioPharmaBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
New Zealand's Medsafe and Pharmac directed to explore AI use to expedite access
July 2, 2025 - - Latest News -
New treatment option for early breast cancer at high risk of recurrence
July 2, 2025 - - Latest News -
Expanded listing for Bristol Myers Squibb's PD-1 to include bladder cancer
July 2, 2025 - - Latest News -
The industry backs productivity focus for the Albanese Government's second term
July 2, 2025 - - Latest News -
Wesfarmers Health launches pilot pharmacy format, InstantScripts Pharmacy Health Hub
July 2, 2025 - - Latest News -
Moderna announces positive Phase 3 result for influenza vaccine
July 1, 2025 - - Latest News -
Takeda therapy now available through the PBS for serious viral infection
July 1, 2025 - - Latest News